Physician profile
Patrick Stevens
NPI 1699065631
$4,661.45
in general payments reported to CMS, 2019-2025
27 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $103 · 2021: $278 · 2022: $707 · 2023: $858 · 2024: $1,296 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,305 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,304.72 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $756.52 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $654.21 | 2023-2025 | Amvuttra |
| Pfizer INC. | $403.21 | 2019-2025 | |
| Medtronic, INC. | $312.03 | 2022-2025 | Aurora Ev-Icd Mri Surescan, Pulseselect |
| Astrazeneca Pharmaceuticals LP | $261.57 | 2020-2025 | Farxiga, Wainua, Andexxa |
| Astellas Pharma US INC | $239.50 | 2019 | |
| Boston Scientific Corporation | $229.45 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.08 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $220.50 | 2022-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $218.32 | 2022-2025 | Camzyos, Eliquis |
| Abiomed | $192.14 | 2023 | Impella |
| Abbott Laboratories | $148.81 | 2021-2025 | Aveir, Amplatzer Amulet, Cardiomems |
| Lantheus Medical Imaging, INC. | $104.76 | 2020-2025 | Definity |
| Cvrx, INC. | $97.09 | 2024-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $92.08 | 2020-2024 | Xarelto |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $72.22 | 2022 | |
| Atricure, INC. | $69.84 | 2022 | |
| Daiichi Sankyo INC. | $68.92 | 2022-2024 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.14 | 2021-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $51.53 | 2025 | |
| Heartflow, INC. | $50.28 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $42.30 | 2023 | Arcalyst |
| Novo Nordisk INC | $30.51 | 2025 | Ozempic |
| Cardiva Medical, INC. | $19.57 | 2025 | Optowire |
| Sanofi-Aventis U.S. LLC | $16.90 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $13.88 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.